Markets
6.4
Novo Raises Full-Year Targets; Analyst Sees Gradual Turnaround
Published 2 d ago6 sourcesEvidence: Reported
SeverityModerateDagens IndustriLow-rated sourceSE
MarketsReportedLow
2.1
Genmab Q3 Revenue Up, Operating Profit Down YoY
Genmab reported Q3 operating profit of DKK 431M, down from DKK 459M a year earlier despite higher revenue. The decline suggests margin compression, likely due to increased R&D or commercialization costs. This is a routine earnings update with no major strategic shift.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Score Breakdown
Mosaic Score2.1
Model confidence0.9
Significance0.1
Source credibility0.3
Related signals
8 foundMarkets
5.6
Novo Nordisk Q3 beats on Wegovy pill, but Eli Lilly lead persists
Published 2 d ago3 sourcesEvidence: Reported
SeverityModerateFDLow-rated sourceDK · US
Markets
5.0
SK Biopharm Q3 Operating Profit Surges 66% on U.S. Seizure Drug Sales
Published 2 d ago1 sourceEvidence: Reported
SeverityModerateYonhap ENLow-rated sourceKR · US
Markets
5.0
Skanska Q3 Order Intake Beats, Operating Profit Misses Expectations
Published 2 d ago1 sourceEvidence: Reported
SeverityModerateDagens IndustriLow-rated sourceSE
Markets
2.1
GN Store Nord Q3 EBITA beats expectations, shares likely to react
Published 2 d ago1 sourceEvidence: Unknown
Dagens IndustriLow-rated sourceDK
Markets
2.1
Camurus Q3 Revenue Beats Expectations, Up 28% YoY
Published 2 d ago1 sourceEvidence: Reported
Dagens IndustriLow-rated sourceSE · US
Markets
2.0
Modivo Platform Q3 FY2026: Adjusted EBITDA Up 48%, Operating Profit Down 14%
Published 1 d ago1 sourceEvidence: Reported
ParkietLow-rated sourcePL
Conflict
9.4
Russian strikes cripple Ukraine drug supply chain, pharmacies empty
Published 2 d ago16 sourcesEvidence: Reported
SeverityHighAssessedDeveloping storyKyiv IndependentUA · RU